Fewer than one in 10 patients who could benefit from obesity jabs like Wegovy have access to them, states the WHO as it publishes its initial guidance on the medications.
Given more than one billion people worldwide currently obese, it is calling for increased and just access to GLP-1 medication.
Per projections, more than two billion are projected to be obese by 2030 unless action is taken.
"Our new guidance acknowledges that obesity is a chronic disease that can be treated with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key obstacles to broad access to the injections that can help people shift substantial body mass, notes the organization.
Weight-Loss Drug Scarcity
Even in the present most optimistic case, the supply of these medications could only cover around 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation encourages nations and manufacturers to widen access, via approaches like voluntary licensing.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Drugs Function
These medications replicate a natural hormone to slow digestion, curb appetite and boost feelings of fullness so people eat less.
Patients usually start to lose weight after several weeks of beginning the regular doses.
Studies indicates people may put most of the weight back on within a year of stopping the drug, when their typical hunger come back.
To be carrying excess weight elevates your risk for developing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity concerns people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the WHO.
